BioTech/Drugs - Boston, Massachusetts, US
Driven by our proprietary Enhanced Delivery Oligonucleotide (EDO) platform, we are creating a pipeline of disease-modifying therapeutics with the potential to safely and effectively target the root cause of serious genetic neuromuscular and neurological disorders.
Outlook
WP Engine
Zendesk
Microsoft Office 365
DigitalOcean